Ocugen to Host a Conference Call on Friday, February 25 at 8:30 a.m. ET to Discuss Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update

Ocugene

MALVERN, Pennsylvania, Feb. 18 11, 2022 (GLOBE NEWSWIRE) — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on the discovery, development and commercialization of gene therapies to cure diseases of blindness and the development of a vaccine to save lives. lives of COVID-19, announced today that it will host a conference call to discuss its fourth quarter and full year 2021 financial results and provide a business update at 8:30 a.m. ET on Friday, February 25 2022.

Ocugen will release a premarket earnings announcement the same day. Investors are invited to participate in the call using the following information:

About Ocugen, Inc.
Ocugen, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gene therapies to cure diseases of blindness and the development of a life-saving vaccine against COVID-19. Our breakthrough gene-modifying therapy platform has the potential to treat multiple retinal diseases with a single drug – “one-to-many” and our new biologic product candidate aims to provide better therapy for patients with underserved diseases such as related macular degeneration. in wet age, diabetic macular disease edema and diabetic retinopathy. We are co-developing Bharat Biotech’s COVAXIN™ vaccine candidate for COVID-19 in the US and Canadian markets. For more information, please visit www.ocugen.com.

Caution Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. These forward-looking statements contained in this press release include, but are not limited to, the intended use of net proceeds from the registered direct offering. We may, in some cases, use terms such as “predicts”, “believes”, “potential”, “proposed”, “continues”, “estimates”, “anticipates”, “expects”, “plans”. , “intends,” “may,” “could,” “could,” “will,” “should,” or other words that convey uncertainty of future events or results to identify these forward-looking statements. These statements are subject to numerous important factors, risks and uncertainties that could cause actual events or results to differ materially from our current expectations, such as market and other conditions. , are described in greater detail in our periodic filings with the Securities and Exchange Commission (the “SEC”), including the risk factors described in the section titled “Risk Factors” in the quarterly and annual reports we file with of the second.All forward-looking statements we make in this press release speak only as of the date of this press release. Except as required by law, we undertake no obligation to update any forward-looking statements contained in this press release, whether as a result of new information, future events or otherwise, after the date of this Press release.

Ocugen contact:
Ken Inchausti
Head, Investor Relations and Communications
[email protected]

Please submit investor inquiries to: [email protected]

Michael P. Boser